'Strong' Vyvgart sales boost Argenx shares

argenx SE

25/07/2024 09:19

** Shares in Argenx  DAST.PA  jump 5.1% after reporting H1
results above market expectations, led by Vyvgart sales beat
    ** The Belgian biopharmaceutical company published an
operating income of $489 million benefiting form a growth in
patients and prescribers in the US, says KBC 
    ** KBC adds that these results are being led by strong sales
for its Vyvgart treatment of $478 million in Q2
    ** "Argenx manages to beat analysts' consensus sales
expectations by 12%, showcasing the robustness of its commercial
engine for the 10th consecutive quarter",-  KBC 
    ** "Comforting update with VYVGART once again beating CSS
expectations", says Degroof Petercam
    ** J.P. Morgan echoes these comments, says Vyvgart beat
should be positively received by the market and expects shares
to outperform today 
    ** Including today's rise the stock has gained 31.3% YTD​

 (Reporting by Mathias de Rozario)
 ((mathias.derozario@thomsonreuters.com))